Milestone Pharmaceuticals Receives NMPA Approval for Etripamil Nasal Spray in China

Milestone Pharmaceuticals (MIST) announced that it has received NMPA approval for its etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT) in China. This marks the first regulatory approval of etripamil outside the U.S., which could significantly impact Milestone's growth outlook and revenue projections by opening a substantial new market.